Several states are considering or have enacted legislation to create prescription drug affordability boards (PDABs). Although their powers vary by state, PDABs are generally charged with assessing the affordability of prescription drugs and developing recommendations to reduce spending; negotiating Medicaid supplemental rebates with manufacturers; and/or setting upper payment limits (UPLs), which seek to limit the amount payers, providers, pharmacies and patients can pay for prescription drugs. In 2024, Colorado’s PDAB—the first in the country to begin conducting affordability reviews—is poised to determine whether to impose a UPL, and PDABs in other states are following Colorado’s lead. The ability of PDABs to implement UPLs, however, faces several operational and legal challenges.
In a new webinar, Manatt Health and thought leaders from PhRMA and Harvard Medical School will examine the current PDAB landscape and the ways it could reshape the pharmaceutical supply chain.
Key questions the program will answer include:
- Which states have PDABs—and what is the status of PDAB activities in each state?
- How does PDABs’ power differ among states?
- How can PDABs attempt to implement a UPL?
- How could a UPL impact the pharmaceutical supply chain?
- What potential legal objections might be raised against UPLs—and how have these arguments fared in the past?
- Michael Kolber, Partner, Manatt Health
- Jonathan DiBello, Manager, Manatt Health
- Benjamin N. Rome, M.D., M.P.H., Instructor in Medicine, Harvard Medical School and Division of Pharmacology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital
- Leslie Wood, Regional Vice President—State Policy, PhRMA
Date and Time
Tuesday, February 27
10:00 – 11:00 a.m. PT
1:00 – 2:00 p.m. ET
If you would like to receive an audio transcript of this webinar due to accessibility issues, please email us at email@example.com.
This program does not constitute legal advice, nor does it establish an attorney-client relationship. Views expressed by presenters are strictly their own and should not be construed to be the views of Manatt or attributed to Manatt.